Header Logo

Connection

Usman Baber to Coronary Artery Disease

Back to Details
This is a "connection" page, showing publications Usman Baber has written about Coronary Artery Disease.
Usman Baber
Connection Strength
21.804
Coronary Artery Disease
  1. Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Less Is Not Always More. JACC Cardiovasc Interv. 2022 06 13; 15(11):1164-1166.
    View in: PubMed
    Score: 0.665
  2. Relationship between hemoglobin A1C and characteristics of plaque vulnerability in stable coronary disease: an optical coherence tomography study. Int J Cardiovasc Imaging. 2022 Feb; 38(2):473-482.
    View in: PubMed
    Score: 0.645
  3. Coronary Artery Calcification and Mortality After Revascularization: Look Beyond the Heart. JACC Cardiovasc Interv. 2022 01 24; 15(2):205-207.
    View in: PubMed
    Score: 0.644
  4. Treating Myocardial Ischemia Before Kidney Transplantation: Time for a Reappraisal. J Am Coll Cardiol. 2021 07 27; 78(4):362-364.
    View in: PubMed
    Score: 0.626
  5. The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial Experience. Interv Cardiol Clin. 2020 10; 9(4):489-498.
    View in: PubMed
    Score: 0.591
  6. Ventricular Fibrillation Associated With Coronary Plaque Erosion Detected by Optical Coherence Tomography. JACC Cardiovasc Interv. 2020 01 13; 13(1):e5-e7.
    View in: PubMed
    Score: 0.559
  7. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 07; 12(7):e007734.
    View in: PubMed
    Score: 0.543
  8. Left Main PCI With DES Versus CABG: Cautionary Note or Cause for Concern? J Am Coll Cardiol. 2018 12 11; 72(23 Pt A):2823-2825.
    View in: PubMed
    Score: 0.521
  9. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). Circ Cardiovasc Interv. 2018 03; 11(3):e006144.
    View in: PubMed
    Score: 0.494
  10. Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry. Coron Artery Dis. 2016 Sep; 27(6):442-8.
    View in: PubMed
    Score: 0.445
  11. Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease. Eur Heart J. 2016 Dec 07; 37(46):3440-3447.
    View in: PubMed
    Score: 0.445
  12. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016 Jan 11; 9(1):28-38.
    View in: PubMed
    Score: 0.426
  13. The Shifting Pendulum for DAPT After PCI: Balancing Long-Term Risks for Bleeding and Thrombosis. J Am Coll Cardiol. 2015 Sep 01; 66(9):1046-9.
    View in: PubMed
    Score: 0.415
  14. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv. 2015 Jun; 8(6):e001683.
    View in: PubMed
    Score: 0.408
  15. Variability in low-density lipoprotein cholesterol and cardiovascular risk: should consistency be a new target? J Am Coll Cardiol. 2015 Apr 21; 65(15):1549-51.
    View in: PubMed
    Score: 0.405
  16. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. J Am Coll Cardiol. 2015 Mar 24; 65(11):1065-74.
    View in: PubMed
    Score: 0.403
  17. Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. Am Heart J. 2013 Aug; 166(2):373-380.e2.
    View in: PubMed
    Score: 0.357
  18. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. JACC Cardiovasc Imaging. 2012 Mar; 5(3 Suppl):S53-61.
    View in: PubMed
    Score: 0.326
  19. Stenting of complex lesions: an overview. Nat Rev Cardiol. 2010 Sep; 7(9):485-96.
    View in: PubMed
    Score: 0.294
  20. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol. 2010 Feb; 22(2):80-3.
    View in: PubMed
    Score: 0.282
  21. Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int. 2008 Mar; 73(5):615-21.
    View in: PubMed
    Score: 0.243
  22. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. Am Heart J. 2007 Apr; 153(4):471-7.
    View in: PubMed
    Score: 0.232
  23. Stent Failure After Percutaneous Coronary Intervention in Diabetes?Mellitus: Does Glycemic Control Matter? J Am Coll Cardiol. 2024 Jul 16; 84(3):273-275.
    View in: PubMed
    Score: 0.192
  24. Prognostic impact of peripheral artery disease in patients with and without high bleeding risk undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2024 Feb; 103(3):425-434.
    View in: PubMed
    Score: 0.186
  25. Intravascular imaging guided versus coronary angiography guided percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2023 11 16; 383:e077848.
    View in: PubMed
    Score: 0.183
  26. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium. Circulation. 2023 06 20; 147(25):1933-1944.
    View in: PubMed
    Score: 0.178
  27. Impact of complex percutaneous coronary intervention features on clinical outcomes in patients with or without chronic kidney disease. Catheter Cardiovasc Interv. 2023 02; 101(3):511-519.
    View in: PubMed
    Score: 0.173
  28. New Criteria to Identify Patients at Higher Risk for Cardiovascular Complications After Percutaneous Coronary Intervention. Am J Cardiol. 2023 02 15; 189:22-30.
    View in: PubMed
    Score: 0.172
  29. Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry. EuroIntervention. 2022 Oct 07; 18(8):e656-e665.
    View in: PubMed
    Score: 0.170
  30. Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI. JACC Cardiovasc Interv. 2021 11 22; 14(22):2447-2457.
    View in: PubMed
    Score: 0.160
  31. Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft. Catheter Cardiovasc Interv. 2021 11 15; 98(6):E785-E795.
    View in: PubMed
    Score: 0.158
  32. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. JAMA Cardiol. 2021 09 01; 6(9):1032-1041.
    View in: PubMed
    Score: 0.157
  33. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021 06 16; 373:n1332.
    View in: PubMed
    Score: 0.155
  34. Relationship between high shear stress and OCT-verified thin-cap fibroatheroma in patients with coronary artery disease. PLoS One. 2020; 15(12):e0244015.
    View in: PubMed
    Score: 0.150
  35. A sex paradox in clinical outcomes following complex percutaneous coronary intervention. Int J Cardiol. 2021 04 15; 329:67-73.
    View in: PubMed
    Score: 0.150
  36. Side branch fractional flow reserve after provisional stenting of calcified bifurcation lesions: The ORBID-FFR study. Catheter Cardiovasc Interv. 2021 10; 98(4):658-668.
    View in: PubMed
    Score: 0.148
  37. Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2020 12 15; 137:1-6.
    View in: PubMed
    Score: 0.148
  38. Influence of final kissing balloon inflation on long-term outcomes after PCI of distal left main bifurcation lesions in the EXCEL trial. EuroIntervention. 2020 Jun 25; 16(3):218-224.
    View in: PubMed
    Score: 0.145
  39. Trends and Outcomes of Intravascular Imaging-guided Percutaneous Coronary Intervention in the United States. Crit Pathw Cardiol. 2020 06; 19(2):69-74.
    View in: PubMed
    Score: 0.144
  40. Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial. Cardiovasc Res. 2020 06 01; 116(7):e70-e72.
    View in: PubMed
    Score: 0.144
  41. One-year outcomes of patients undergoing complex percutaneous coronary intervention with three contemporary drug-eluting stents. Catheter Cardiovasc Interv. 2021 06 01; 97(7):1341-1351.
    View in: PubMed
    Score: 0.144
  42. 1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration. Cardiovasc Revasc Med. 2020 12; 21(12):1542-1547.
    View in: PubMed
    Score: 0.144
  43. Outcomes of Impella-supported high-risk nonemergent percutaneous coronary intervention in a large single-center registry. Catheter Cardiovasc Interv. 2021 01 01; 97(1):E26-E33.
    View in: PubMed
    Score: 0.143
  44. Comparison of One-Year Outcomes in Patients >75 Versus =75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). Am J Cardiol. 2020 07 15; 127:1-8.
    View in: PubMed
    Score: 0.143
  45. 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents. JACC Cardiovasc Interv. 2020 04 13; 13(7):820-830.
    View in: PubMed
    Score: 0.143
  46. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. Circ Cardiovasc Interv. 2020 04; 13(4):e008226.
    View in: PubMed
    Score: 0.143
  47. Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. Catheter Cardiovasc Interv. 2021 04 01; 97(5):797-804.
    View in: PubMed
    Score: 0.142
  48. Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. Catheter Cardiovasc Interv. 2020 08; 96(2):298-308.
    View in: PubMed
    Score: 0.142
  49. Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large single-center registry. Catheter Cardiovasc Interv. 2020 09 01; 96(3):E278-E286.
    View in: PubMed
    Score: 0.142
  50. 1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration. Int J Cardiol. 2020 05 15; 307:17-23.
    View in: PubMed
    Score: 0.141
  51. Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy. Catheter Cardiovasc Interv. 2020 10 01; 96(4):793-801.
    View in: PubMed
    Score: 0.139
  52. Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry. Catheter Cardiovasc Interv. 2020 09 01; 96(3):558-564.
    View in: PubMed
    Score: 0.137
  53. Stent Expansion and Endothelial Shear Stress in Bifurcation Lesions. Circ Cardiovasc Interv. 2019 06; 12(6):e007911.
    View in: PubMed
    Score: 0.135
  54. Incidence, determinants and impact of acute kidney injury in patients with diabetes mellitus and multivessel disease undergoing coronary revascularization: Results from the FREEDOM trial. Int J Cardiol. 2019 10 15; 293:197-202.
    View in: PubMed
    Score: 0.135
  55. Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2019 05 21; 73(19):2401-2409.
    View in: PubMed
    Score: 0.134
  56. Procedural and one-year outcomes of patients treated with orbital and rotational atherectomy with mechanistic insights from optical coherence tomography. EuroIntervention. 2019 Apr 20; 14(17):1760-1767.
    View in: PubMed
    Score: 0.134
  57. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 04; 12(4):e007133.
    View in: PubMed
    Score: 0.133
  58. Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Am J Cardiol. 2019 06 01; 123(11):1788-1795.
    View in: PubMed
    Score: 0.133
  59. Calculated Serum Osmolality, Acute Kidney Injury, and Relationship to Mortality after Percutaneous Coronary Intervention. Cardiorenal Med. 2019; 9(3):160-167.
    View in: PubMed
    Score: 0.133
  60. Safety and Efficacy of Polymer-Free Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 02; 12(2):e007311.
    View in: PubMed
    Score: 0.132
  61. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. Int J Cardiol. 2019 05 15; 283:67-72.
    View in: PubMed
    Score: 0.131
  62. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J. 2018 12 07; 39(46):4101-4108.
    View in: PubMed
    Score: 0.130
  63. Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. Catheter Cardiovasc Interv. 2019 05 01; 93(6):1124-1131.
    View in: PubMed
    Score: 0.130
  64. Predictors of side branch compromise in calcified bifurcation lesions treated with orbital atherectomy. Catheter Cardiovasc Interv. 2019 07 01; 94(1):45-52.
    View in: PubMed
    Score: 0.130
  65. Assessing and minimizing the risk of percutaneous coronary intervention in patients with chronic kidney disease. Expert Rev Cardiovasc Ther. 2018 Nov; 16(11):825-835.
    View in: PubMed
    Score: 0.129
  66. 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration. JACC Cardiovasc Interv. 2018 10 08; 11(19):1969-1978.
    View in: PubMed
    Score: 0.129
  67. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. Eur Heart J Cardiovasc Imaging. 2018 09 01; 19(9):1042-1050.
    View in: PubMed
    Score: 0.128
  68. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). Am J Cardiol. 2018 11 15; 122(10):1638-1646.
    View in: PubMed
    Score: 0.128
  69. Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions. J Invasive Cardiol. 2018 07; 30(7):251-255.
    View in: PubMed
    Score: 0.125
  70. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. JACC Cardiovasc Interv. 2018 01 08; 11(1):53-65.
    View in: PubMed
    Score: 0.122
  71. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.119
  72. Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. Catheter Cardiovasc Interv. 2018 04 01; 91(5):859-866.
    View in: PubMed
    Score: 0.118
  73. Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). Am J Cardiol. 2017 Sep 15; 120(6):904-910.
    View in: PubMed
    Score: 0.118
  74. Mid-term outcomes of consecutive 998 cases of coronary atherectomy in contemporary clinical practice. J Interv Cardiol. 2017 Aug; 30(4):331-337.
    View in: PubMed
    Score: 0.118
  75. Percutaneous Coronary Intervention Outcomes in Very Elderly Patients From a Single Large-Volume Tertiary Care Center, Specifically Focusing on Nonagenarians. JACC Cardiovasc Interv. 2017 06 26; 10(12):1273-1274.
    View in: PubMed
    Score: 0.118
  76. Three-dimensional volumetric assessment of coronary artery calcification in patients with stable coronary artery disease by OCT. EuroIntervention. 2017 Jun 20; 13(3):312-319.
    View in: PubMed
    Score: 0.118
  77. Improving Outcomes in High-Risk Percutaneous Coronary Interventions and Newer-Generation Drug-Eluting Stents: Good, But Not Good Enough. Cardiology. 2017; 138(2):73-75.
    View in: PubMed
    Score: 0.118
  78. Increased Lipid Length, Macrophage Infiltration, and Neovascularization in Coronary Atheroma From Patients With Chronic Kidney Disease. JACC Cardiovasc Imaging. 2017 12; 10(12):1524-1526.
    View in: PubMed
    Score: 0.116
  79. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. JACC Cardiovasc Interv. 2017 04 10; 10(7):645-654.
    View in: PubMed
    Score: 0.116
  80. Quantitative angiographic characterisation of coronary artery disease in patients with human immunodeficiency virus (HIV) infection undergoing percutaneous coronary intervention. EuroIntervention. 2017 Feb 20; 12(14):1757-1765.
    View in: PubMed
    Score: 0.115
  81. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Circ Cardiovasc Interv. 2017 02; 10(2).
    View in: PubMed
    Score: 0.115
  82. Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. Am J Cardiol. 2017 04 15; 119(8):1166-1172.
    View in: PubMed
    Score: 0.114
  83. Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials. Int J Cardiol. 2017 Mar 01; 230:310-318.
    View in: PubMed
    Score: 0.114
  84. Multiethnic Exome-Wide Association Study of Subclinical Atherosclerosis. Circ Cardiovasc Genet. 2016 Dec; 9(6):511-520.
    View in: PubMed
    Score: 0.113
  85. Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment: The YELLOW II Study. J Am Coll Cardiol. 2017 Feb 14; 69(6):628-640.
    View in: PubMed
    Score: 0.113
  86. Fibrous Cap Thickness by Optical Coherence Tomography In Vivo. J Am Coll Cardiol. 2017 Feb 14; 69(6):644-657.
    View in: PubMed
    Score: 0.113
  87. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovasc Interv. 2016 09 26; 9(18):1890-901.
    View in: PubMed
    Score: 0.112
  88. A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study. J Am Coll Cardiol. 2016 08 30; 68(9):881-91.
    View in: PubMed
    Score: 0.111
  89. Plaque Morphology Predictors of Side Branch Occlusion After Main Vessel Stenting in Coronary Bifurcation Lesions: Optical Coherence Tomography Imaging Study. JACC Cardiovasc Interv. 2016 Apr 25; 9(8):862-865.
    View in: PubMed
    Score: 0.109
  90. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. JACC Cardiovasc Interv. 2016 Apr 11; 9(7):674-84.
    View in: PubMed
    Score: 0.108
  91. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 15; 117(12):1877-83.
    View in: PubMed
    Score: 0.108
  92. Multimodality Intravascular Imaging to Evaluate Sex Differences in Plaque Morphology in Stable CAD. JACC Cardiovasc Imaging. 2016 Apr; 9(4):400-7.
    View in: PubMed
    Score: 0.108
  93. Digital Mammography and Screening for Coronary Artery Disease. JACC Cardiovasc Imaging. 2016 Apr; 9(4):350-60.
    View in: PubMed
    Score: 0.108
  94. Plaque morphology predictors of side branch occlusion after provisional stenting in coronary bifurcation lesion: Results of optical coherence tomography bifurcation study (ORBID). Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):259-268.
    View in: PubMed
    Score: 0.108
  95. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016 Sep 06; 134(10):e156-78.
    View in: PubMed
    Score: 0.108
  96. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 09 06; 68(10):1116-39.
    View in: PubMed
    Score: 0.108
  97. Association of APOC3 Loss-of-Function Mutations With Plasma Lipids and Subclinical Atherosclerosis: The Multi-Ethnic BioImage Study. J Am Coll Cardiol. 2015 Nov 03; 66(18):2053-2055.
    View in: PubMed
    Score: 0.105
  98. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study. Catheter Cardiovasc Interv. 2016 Mar; 87(4):703-9.
    View in: PubMed
    Score: 0.105
  99. Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry. Am Heart J. 2015 Dec; 170(6):1234-42.
    View in: PubMed
    Score: 0.104
  100. Incremental prognostic value of coronary computed tomographic angiography high-risk plaque characteristics in newly symptomatic patients. J Cardiol. 2016 06; 67(6):538-44.
    View in: PubMed
    Score: 0.104
  101. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015 Sep 15; 116(6):845-52.
    View in: PubMed
    Score: 0.103
  102. Multimodality Intravascular Imaging to Predict Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2015 Jun; 8(7):937-45.
    View in: PubMed
    Score: 0.102
  103. Optical coherence tomography assessment of the mechanistic effects of rotational and orbital atherectomy in severely calcified coronary lesions. Catheter Cardiovasc Interv. 2015 Nov 15; 86(6):1024-32.
    View in: PubMed
    Score: 0.102
  104. Comparison of provisional 1-stent and 2-stent strategies in diabetic patients with true bifurcation lesions: the EES bifurcation study. J Invasive Cardiol. 2014 Dec; 26(12):619-23.
    View in: PubMed
    Score: 0.099
  105. The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study. Eur Heart J Cardiovasc Imaging. 2015 Jan; 16(1):81-7.
    View in: PubMed
    Score: 0.097
  106. Dedicated two-stent technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: the EES-bifurcation study. Int J Cardiol. 2014 Jun 01; 174(1):13-7.
    View in: PubMed
    Score: 0.094
  107. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet. 2013 Dec 07; 382(9908):1879-88.
    View in: PubMed
    Score: 0.090
  108. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013 Nov 23; 382(9906):1714-22.
    View in: PubMed
    Score: 0.090
  109. Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI: competing factors influence mortality, myocardial infarction, and target lesion revascularization. Catheter Cardiovasc Interv. 2013 Nov 15; 82(6):855-68.
    View in: PubMed
    Score: 0.089
  110. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013 Jul 02; 62(1):21-9.
    View in: PubMed
    Score: 0.088
  111. Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. J Interv Cardiol. 2012 Oct; 25(5):482-92.
    View in: PubMed
    Score: 0.083
  112. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging. 2012 May; 5(5):540-9.
    View in: PubMed
    Score: 0.082
  113. Female gender and mortality after percutaneous coronary intervention: results from a large registry. Catheter Cardiovasc Interv. 2012 Oct 01; 80(4):514-21.
    View in: PubMed
    Score: 0.080
  114. Combined role of reduced estimated glomerular filtration rate and microalbuminuria on the prevalence of peripheral arterial disease. Am J Cardiol. 2009 Nov 15; 104(10):1446-51.
    View in: PubMed
    Score: 0.070
  115. Machine learning prediction in cardiovascular diseases: a meta-analysis. Sci Rep. 2020 09 29; 10(1):16057.
    View in: PubMed
    Score: 0.037
  116. A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS Genet. 2020 04; 16(4):e1008629.
    View in: PubMed
    Score: 0.036
  117. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thromb Haemost. 2019 10; 119(10):1704-1711.
    View in: PubMed
    Score: 0.034
  118. Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet. 2017 Dec; 49(12):1758-1766.
    View in: PubMed
    Score: 0.030
  119. Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. Clin Pharmacol Ther. 2016 09; 100(3):287-94.
    View in: PubMed
    Score: 0.027
  120. Gender-specific outcomes after balloon aortic valvuloplasty: Inhospital and long-term outcomes. Am Heart J. 2015 Jul; 170(1):180-6.
    View in: PubMed
    Score: 0.025
  121. An allele-specific PCR system for rapid detection and discrimination of the CYP2C19*4A, *4B, and *17 alleles: implications for clopidogrel response testing. J Mol Diagn. 2013 Nov; 15(6):783-9.
    View in: PubMed
    Score: 0.023
  122. High-efficiency SPECT MPI: comparison of automated quantification, visual interpretation, and coronary angiography. J Nucl Cardiol. 2013 Oct; 20(5):763-73.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.